Crinetics Pharmaceuticals CRNX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $18.07M+2,278% | $7.7M+641% | $1.54M+47.7% | $1.39M+0.5% | $760K-61.5% | ||
| —— | —— | —— | —— | $0— | ||
| —— | —— | —— | —— | $1.14M-65.1% | ||
| $355.9M+35.3% | $332.06M+38.3% | $313.57M+43.1% | $285.01M+41.7% | $263.06M+43.4% | ||
| —— | $191.33M+91.8% | $168.43M+88.6% | $145.53M+84.4% | $122.64M+79.0% | ||
| —— | —— | $165.81M+87.1% | $139.44M+78.2% | $114.44M+71.5% | ||
| —— | —— | —— | —— | $366.69M+43.8% | ||
| -$545.74M-44.9% | -$516.77M-52.5% | -$477.85M-55.8% | -$423.06M-52.2% | -$376.73M-51.8% | ||
| -3,020.3%+46,549pp | -6,714.8%+25,899pp | -31,130.2%-1,605pp | -30,392.2%-10,324pp | -49,569.7%-36,998pp | ||
| $49.82M+1.8% | $51.99M+25.5% | $55.2M+63.4% | $53.66M+112% | $48.95M+162% | ||
| $49.53M+2.2% | $51.63M+26.2% | $54.75M+63.3% | $53.23M+112% | $48.48M+164% | ||
| —— | $180K— | $135K— | $90K— | $45K— | ||
| -$496.39M-51.2% | -$465.32M-55.9% | -$423.1M-52.2% | -$369.83M-43.0% | -$328.25M-39.4% | ||
| -2,747.2%+40,444pp | -6,046.2%+22,674pp | -27,563.3%-815pp | -26,568.5%-7,901pp | -43,191.1%-31,263pp | ||
| -$5.13-34.6% | -$4.94-33.5% | -$4.52-21.8% | -$4.10-9.0% | -$3.81-1.3% | ||
| -$5.13-34.6% | -$4.94-33.5% | -$4.52-21.8% | -$4.10-9.0% | -$3.81-1.3% | ||
| 386.2M+16.0% | 375.2M+20.2% | 361.9M+25.0% | 347.8M+30.7% | 333M+37.9% | ||
| 386.2M+16.0% | 375.2M+20.2% | 361.9M+25.0% | 347.8M+30.7% | 333M+37.9% | ||
| -$499.64M-53.1% | -$464.42M-55.6% | -$422.94M-53.8% | -$368.02M-43.2% | -$326.4M-40.2% | ||
| —— | -$465.32M-56.2% | -$423.47M-53.6% | -$381.63M-50.5% | -$339.78M-46.8% | ||
| -$150K-2,600% | -$172K— | -$49K— | -$28K— | $6K— | ||
| —— | —— | $205K-92.9% | $1.84M+21.4% | $1.85M-30.7% | ||
| -$305K— | -$377K— | -$470K— | -$458K— | —— | ||
| $18.07M+2,278% | $7.7M+641% | $1.54M+47.7% | $1.39M+0.5% | $760K-61.5% | ||
| -$545.74M-44.9% | -$516.77M-52.5% | -$477.85M-55.8% | -$423.06M-52.2% | -$376.73M-51.8% | ||
| -$541.62M-45.0% | -$512.88M-52.6% | -$474.16M-55.7% | -$419.62M-51.9% | -$373.49M-51.3% | ||
| -$541.62M-45.0% | -$512.88M-52.6% | -$474.16M-55.7% | -$419.62M-51.9% | -$373.49M-51.3% | ||
| -2,997.5%+46,146pp | -6,664.2%+25,681pp | -30,890.2%-1,582pp | -30,144.9%-10,204pp | -49,143.9%-36,638pp | ||
| -$545.74M-44.9% | -$516.77M-52.5% | -$477.85M-55.8% | -$423.06M-52.2% | -$376.73M-51.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Crinetics Pharmaceuticals's profit margins?
- Gross margin is 150.0% and operating margin is -3020.3%, with a -2747.2% net margin.
- Where does Crinetics Pharmaceuticals's income statement data come from?
- Every line is extracted from Crinetics Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.